Gastrointestinal Dysmotility Clinical Trial
Official title:
Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection w/Primary Anastomosis
Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01285570 -
Ulimorelin Study of Efficacy and Safety (ULISES 007)
|
Phase 3 | |
Completed |
NCT01296620 -
Ulimorelin Study of Efficacy and Safety (ULISES 008)
|
Phase 3 | |
Withdrawn |
NCT04872452 -
Analysis of Cutaneous Nerve Biopsies in Gastrointestinal Motility Disorders
|
N/A | |
Completed |
NCT04880538 -
Enteric Neural Precursor Cells (ENPC) in the Human Gut
|